Gold continues to challenge its all-time high set in October 2024, and many analysts believe that the precious metal can reach $3,000 per troy ounce by the end of 2025.
About This EventBeta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the design, development of advanced diabetes management solutions, visits the Nasdaq MarketSite in Times Square.In honor of ...
Even though Ternium stock trades at 66% of its 52-week high today, its valuations still call for premiums over peers and the rest of the industry. More specifically, the company’s price-to-earnings (P ...
Written by Nikolaus Hoffman for Bitcoin Magazine -> ...
That reason is already being taken to the bank by options traders, who recently bought up to 25,831 call options, translating into a 159% boost from the company’s usual 9,972 options volume. As with ...
The Consumer Discretionary Select Sector SPDR Fund tracks the Consumer Discretionary Select Sector Index, encompassing industries such as retail, media, hotels, leisure, apparel, automobiles, and ...
“There’s an enormous amount of complexity that’s been brought into the world.” said Nasdaq’s Chair and CEO Adena Friedman at the World Economic Forum’s panel The Future of Growth. “There’s a huge ...
Blackwell production has ramped up to 100%; there are plans for capacity expansion, including into the U.S., and the next-gen technology will soon be available. Rubin, the next iteration of NVIDIA’s ...
This article looks at three stocks with solid insider and institutional buying in Q4 2024 and determines whether they are suitable for 2025. B&G Foods (NYSE: BGS) is a small-cap consumer staple with ...
The technical outlook is favorable for traders. AMD stock is trading at a discount to its 50-day moving average and is close to its 52-week low. Plus, the Relative Strength Indicator (RSI) is around ...
Analysts have assigned the stock a consensus rating of Hold, with an average price target of $38.38, suggesting a potential upside of around 11%. Energizer's stock currently offers a dividend yield of ...
Sana is a gene and cell therapy clinical-stage biotech firm and a penny stock that has fallen by 48.5% in the year leading to January 17, 2025. What may set this company apart from a host of similar ...